Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines

Beate Pesch, Dirk Taeger, Georg Johnen, Katarzyna Gawrych, Nadine Bonberg, Christian Schwentner, Harald Wellhäußer, Matthias Kluckert, Gabriele Leng, Michael Nasterlack, Yair Lotan, Arnulf Stenzl, Thomas Brüning

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: To validate urinary markers for the early detection of bladder cancer (BC) in chemical workers.

Methods: UroScreen was conducted as a validation study for tumor markers within the frame of a health surveillance program of the German Social Accident Insurance for active or retired workers with former exposure to aromatic amines. From 2003 to 2010, 1,609 men took part in voluntary annual screens. Cytology, the quantitative NMP22® assay, and UroVysion™ were applied to 7,091 urine samples.

Results: Fifteen out of 21 tumors were detected following test positivity. The UroVysion/NMP22 panel detected 14 out of 21 tumors versus 8 tumors with cytology alone (sensitivity 66.7 vs. 44.4 %, specificity 94.5 vs. 98.5 %). The sensitivity of the panel increased to 85.7 % in samples collected ≤12 months before diagnosis and when papillomas were excluded, compared to 58.3 % with cytology. About 3 % of NMP22 tests were false-positive. UroVysion results overlapped with cytology due to the preselection of atypical cells. NMP22 was less and UroVysion more frequently positive in diluted urine samples. Leukocytes confounded NMP22 but not UroVysion. The low incidence of BC in this study population yielded low positive predictive values of the markers and high costs per tumor detected with screening.

Conclusions: UroVysion in combination with NMP22 detected more cases than cytology alone, at the expense of a lower specificity. High costs per detected case resulted from a lower BC incidence than in the past when levels of occupational exposure to aromatic amines were higher. Currently, it cannot be recommended to apply these markers for screening in asymptomatic workers. The increase in sensitivity is not balanced by the high costs of UroVysion and the false-positive tests of NMP22.

Original languageEnglish (US)
Pages (from-to)715-724
Number of pages10
JournalInternational Archives of Occupational and Environmental Health
Volume87
Issue number7
DOIs
StatePublished - 2013

Fingerprint

Tumor Biomarkers
Urinary Bladder Neoplasms
Amines
Cell Biology
Costs and Cost Analysis
Neoplasms
Accident Insurance
Urine
Social Security
Validation Studies
Incidence
Papilloma
Occupational Exposure
nuclear matrix protein 22
Early Detection of Cancer
Leukocytes
Health
Population

Keywords

  • Aromatic amines
  • Bladder cancer
  • Chemical workers
  • Cytology
  • NMP22
  • Screening
  • UroVysion
  • Validation study

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. / Pesch, Beate; Taeger, Dirk; Johnen, Georg; Gawrych, Katarzyna; Bonberg, Nadine; Schwentner, Christian; Wellhäußer, Harald; Kluckert, Matthias; Leng, Gabriele; Nasterlack, Michael; Lotan, Yair; Stenzl, Arnulf; Brüning, Thomas.

In: International Archives of Occupational and Environmental Health, Vol. 87, No. 7, 2013, p. 715-724.

Research output: Contribution to journalArticle

Pesch, B, Taeger, D, Johnen, G, Gawrych, K, Bonberg, N, Schwentner, C, Wellhäußer, H, Kluckert, M, Leng, G, Nasterlack, M, Lotan, Y, Stenzl, A & Brüning, T 2013, 'Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines', International Archives of Occupational and Environmental Health, vol. 87, no. 7, pp. 715-724. https://doi.org/10.1007/s00420-013-0916-3
Pesch, Beate ; Taeger, Dirk ; Johnen, Georg ; Gawrych, Katarzyna ; Bonberg, Nadine ; Schwentner, Christian ; Wellhäußer, Harald ; Kluckert, Matthias ; Leng, Gabriele ; Nasterlack, Michael ; Lotan, Yair ; Stenzl, Arnulf ; Brüning, Thomas. / Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. In: International Archives of Occupational and Environmental Health. 2013 ; Vol. 87, No. 7. pp. 715-724.
@article{fe1b634b59e449fabe6af0b7c26f1012,
title = "Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines",
abstract = "Purpose: To validate urinary markers for the early detection of bladder cancer (BC) in chemical workers.Methods: UroScreen was conducted as a validation study for tumor markers within the frame of a health surveillance program of the German Social Accident Insurance for active or retired workers with former exposure to aromatic amines. From 2003 to 2010, 1,609 men took part in voluntary annual screens. Cytology, the quantitative NMP22{\circledR} assay, and UroVysion™ were applied to 7,091 urine samples.Results: Fifteen out of 21 tumors were detected following test positivity. The UroVysion/NMP22 panel detected 14 out of 21 tumors versus 8 tumors with cytology alone (sensitivity 66.7 vs. 44.4 {\%}, specificity 94.5 vs. 98.5 {\%}). The sensitivity of the panel increased to 85.7 {\%} in samples collected ≤12 months before diagnosis and when papillomas were excluded, compared to 58.3 {\%} with cytology. About 3 {\%} of NMP22 tests were false-positive. UroVysion results overlapped with cytology due to the preselection of atypical cells. NMP22 was less and UroVysion more frequently positive in diluted urine samples. Leukocytes confounded NMP22 but not UroVysion. The low incidence of BC in this study population yielded low positive predictive values of the markers and high costs per tumor detected with screening.Conclusions: UroVysion in combination with NMP22 detected more cases than cytology alone, at the expense of a lower specificity. High costs per detected case resulted from a lower BC incidence than in the past when levels of occupational exposure to aromatic amines were higher. Currently, it cannot be recommended to apply these markers for screening in asymptomatic workers. The increase in sensitivity is not balanced by the high costs of UroVysion and the false-positive tests of NMP22.",
keywords = "Aromatic amines, Bladder cancer, Chemical workers, Cytology, NMP22, Screening, UroVysion, Validation study",
author = "Beate Pesch and Dirk Taeger and Georg Johnen and Katarzyna Gawrych and Nadine Bonberg and Christian Schwentner and Harald Wellh{\"a}u{\ss}er and Matthias Kluckert and Gabriele Leng and Michael Nasterlack and Yair Lotan and Arnulf Stenzl and Thomas Br{\"u}ning",
year = "2013",
doi = "10.1007/s00420-013-0916-3",
language = "English (US)",
volume = "87",
pages = "715--724",
journal = "International Archives of Occupational and Environmental Health",
issn = "0340-0131",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines

AU - Pesch, Beate

AU - Taeger, Dirk

AU - Johnen, Georg

AU - Gawrych, Katarzyna

AU - Bonberg, Nadine

AU - Schwentner, Christian

AU - Wellhäußer, Harald

AU - Kluckert, Matthias

AU - Leng, Gabriele

AU - Nasterlack, Michael

AU - Lotan, Yair

AU - Stenzl, Arnulf

AU - Brüning, Thomas

PY - 2013

Y1 - 2013

N2 - Purpose: To validate urinary markers for the early detection of bladder cancer (BC) in chemical workers.Methods: UroScreen was conducted as a validation study for tumor markers within the frame of a health surveillance program of the German Social Accident Insurance for active or retired workers with former exposure to aromatic amines. From 2003 to 2010, 1,609 men took part in voluntary annual screens. Cytology, the quantitative NMP22® assay, and UroVysion™ were applied to 7,091 urine samples.Results: Fifteen out of 21 tumors were detected following test positivity. The UroVysion/NMP22 panel detected 14 out of 21 tumors versus 8 tumors with cytology alone (sensitivity 66.7 vs. 44.4 %, specificity 94.5 vs. 98.5 %). The sensitivity of the panel increased to 85.7 % in samples collected ≤12 months before diagnosis and when papillomas were excluded, compared to 58.3 % with cytology. About 3 % of NMP22 tests were false-positive. UroVysion results overlapped with cytology due to the preselection of atypical cells. NMP22 was less and UroVysion more frequently positive in diluted urine samples. Leukocytes confounded NMP22 but not UroVysion. The low incidence of BC in this study population yielded low positive predictive values of the markers and high costs per tumor detected with screening.Conclusions: UroVysion in combination with NMP22 detected more cases than cytology alone, at the expense of a lower specificity. High costs per detected case resulted from a lower BC incidence than in the past when levels of occupational exposure to aromatic amines were higher. Currently, it cannot be recommended to apply these markers for screening in asymptomatic workers. The increase in sensitivity is not balanced by the high costs of UroVysion and the false-positive tests of NMP22.

AB - Purpose: To validate urinary markers for the early detection of bladder cancer (BC) in chemical workers.Methods: UroScreen was conducted as a validation study for tumor markers within the frame of a health surveillance program of the German Social Accident Insurance for active or retired workers with former exposure to aromatic amines. From 2003 to 2010, 1,609 men took part in voluntary annual screens. Cytology, the quantitative NMP22® assay, and UroVysion™ were applied to 7,091 urine samples.Results: Fifteen out of 21 tumors were detected following test positivity. The UroVysion/NMP22 panel detected 14 out of 21 tumors versus 8 tumors with cytology alone (sensitivity 66.7 vs. 44.4 %, specificity 94.5 vs. 98.5 %). The sensitivity of the panel increased to 85.7 % in samples collected ≤12 months before diagnosis and when papillomas were excluded, compared to 58.3 % with cytology. About 3 % of NMP22 tests were false-positive. UroVysion results overlapped with cytology due to the preselection of atypical cells. NMP22 was less and UroVysion more frequently positive in diluted urine samples. Leukocytes confounded NMP22 but not UroVysion. The low incidence of BC in this study population yielded low positive predictive values of the markers and high costs per tumor detected with screening.Conclusions: UroVysion in combination with NMP22 detected more cases than cytology alone, at the expense of a lower specificity. High costs per detected case resulted from a lower BC incidence than in the past when levels of occupational exposure to aromatic amines were higher. Currently, it cannot be recommended to apply these markers for screening in asymptomatic workers. The increase in sensitivity is not balanced by the high costs of UroVysion and the false-positive tests of NMP22.

KW - Aromatic amines

KW - Bladder cancer

KW - Chemical workers

KW - Cytology

KW - NMP22

KW - Screening

KW - UroVysion

KW - Validation study

UR - http://www.scopus.com/inward/record.url?scp=84909990608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909990608&partnerID=8YFLogxK

U2 - 10.1007/s00420-013-0916-3

DO - 10.1007/s00420-013-0916-3

M3 - Article

C2 - 24129706

AN - SCOPUS:84909990608

VL - 87

SP - 715

EP - 724

JO - International Archives of Occupational and Environmental Health

JF - International Archives of Occupational and Environmental Health

SN - 0340-0131

IS - 7

ER -